The launch of Respiratory Investigation and its scope  by Nukiwa, Toshihiro
Contents lists available at SciVerse ScienceDirectRespiratory Investigation
R e s p i r a t o r y I n v e s t i g a t i o n 5 0 ( 2 0 1 2 ) 1 – 2journal homepage: www.elsevier.com/locate/resinvEditorialThe launch of Respiratory Investigation and its scopeIn March 2012, the Japanese Respiratory Society (JRS)
intends to launch its official English journal, Respiratory
Investigation, as an online-based journal.
The JRS was established in 1961 as a society for respiratory
science and medicine, independent of the traditional tuber-
culosis society. Therefore, the JRS has a history spanning
more than 50 years. In 1988, the JRS joined with its sister
societies in neighboring Asian countries, as well as in Pan-
Pacific countries, to establish the Asian Pacific Society of
Respirology (APSR). In 2000, the JRS began the international
session in its annual scientific meeting. Currently, we
mutually invite researchers from the American Thoracic
Society (ATS), the European Respiratory Society (ERS), and
our homegrown APSR to the annual JRS meeting. In 2006, we
introduced the Scientific Assemblies of the JRS structure and
its annual meeting. This consists of 10 assemblies: Cell and
Molecular Biology (CMB); Allergy, Immunology, and Inflam-
mation (AII); Structure and Function (SF); Obstructive Lung
Diseases (OLD); Diffuse Lung Diseases (DLD); Infectious and
Tuberculosis (IT); Thoracic Oncology (TO); Respiratory Care
(RC); Clinical Problems (CP); and Pulmonary Circulation and
Lung Injury (PCLI). Both senior and young JRS physicians in
their respective assemblies now actively join and work with
similar assemblies in the ATS, ERS, and APSR to create the
best program at the meeting, and publish their research in a
number of English language journals. Through these interna-
tional and domestic scientific and clinical research activities,
and based on the current developments in electronic publish-
ing, we, the JRS, believe that it is an opportune time to realize
our long-incubated plan of launching an English language
journal.
Respiratory medicine covers a huge range of diseases, as
exemplified in the names of our 10 Scientific Assemblies.
However, during the 20th century, the major respiratory
diseases have shifted significantly – from infectious diseases
to inflammatory diseases, and finally to malignant diseases –
as a result of lifestyle and societal changes due to industrial
development, the tobacco epidemic, public health control,
and the aging of population. However, respiratory medicine
has used state-of-the-art imaging techniques since the early
20th century, due to the advantages of air–water contrast in
chest X-ray. In addition, the discovery of antibiotics has also
dramatically changed the treatment of infectious respiratory
diseases. The era of pulmonary physiology in the 1960s
provided an understanding of chronic obstructive pulmonarydisease and bronchial asthma, and pulmonary care medicine
developed as result of lung function research. The current
major disease targets are lung cancer, malignant mesothelio-
ma, and chronic inflammatory diseases such as idiopathic
pulmonary fibrosis. In pursuit of better interventions for
these diseases, scientific research on the pathogenesis of
chronic and non-infectious diseases is indispensable.
A basic question in our field that needs to be addressed is
‘‘what is the biology of the lung in health and disease?’’
During lung morphogenesis, the endoderm evolves into the
airway and alveolar epithelium, and mesenchymal progenitor
cells evolve into alveolar capillaries for gas exchange. These
components merge long before birth, when inspiration and
expiration begin, at approximately 15 weeks of embryonic
development. Although we do not yet fully understand how
lung carcinogenesis occurs, or the molecular and cellular
mechanisms underlying lung fibrosis formation, our under-
standing is developing rapidly. The technical developments of
genetically modified animals such as knockout mice and GFP-
tagging methods have provided modern tools for elucidating
complicated molecular and cellular mechanisms. Recombi-
nant DNA techniques that were developed in the early 1970s
opened the door to the human genome project in 1993.
Incredible technical developments and those in computer
science enabled completion of the mapping and decoding of
the human genome in 2001. More recently, this knowledge
has been combined with the microarray technique to develop
expression microarrays, SNP microarrays, the ChIP-chip
technique, and tiling microarrays, and also the analysis of
data using computational medicine. In the near future, next-
generation sequencing will enable personal genome informa-
tion to be utilized in the clinical setting.
Currently, the 21st century respiratory medicine has already
started using targeted therapy for lung cancer, ahead of other
medical specialties. For example, the discovery of the EGFR
driver mutation is changing the notion of cancer treatment.
Three important messages emerge from a diagnosis of EGFR
driver mutation and treatment with kinase inhibitors, all
profoundly related to lung biology and Asian ethnicity.
First, the basic understanding that the signaling conse-
quence of the EGFR driver mutation imparts a ‘‘gain of
function’’ for cancer cell survival. This alters the notion that
cancer is simply a proliferative disease, since anti-apoptosis
and survival of cancer cells play an essential role. The
mesmerizing ‘‘super-responder’’ effect of short-term tumor
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death mechanism through shutting down the strong survival
signal.
Second, the EGFR driver mutation is lung tissue specific.
Most (although not 100%) of patients showing a super-
response to these targeting inhibitors are patients with lung
adenocarcinoma, and a small percentage have squamous cell
carcinoma. However, no such effect was observed in patients
who have other organ tumors such as gastrointestinal cancer,
breast cancer, or brain cancer. This suggests a novel idea that
lung cancers probably involve a system of differentiated lung
epithelial cells. In this regard, although the specialty of
medical oncology emerged in the United States of America,
chest physicians can share the treatments for patients with
lung cancer based on their knowledge of lung biology.
Third, there is a high incidence of the EGFR mutation
among Asians. Surprisingly, in Japan, Korea, and China,
nearly 70–75% of non-smokers with lung adenocarcinoma
are diagnosed as harboring the EGFR driver mutation. This
leads to the novel concept that the mechanism of lung
carcinogenesis is not always universal, since some mechan-
isms may have an ethnic-dependent genomic background.
In the 21st century, genome-based, personalized, and
computational medicine will develop more rapidly than
currently estimated. Because Respiratory Investigation will be
launched in this exciting era of computational medicine, a
particular emphasis should be placed on studies of disease
mechanisms based on Asian ethnicity, because these me-
chanisms would not draw attention in journals from other
geographical areas. We have already recognized that diffuse
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Furthermore, common diseases, such as chronic obstructive
pulmonary disease and asthma, might have emerged from a
different genomic background in Asians. In the 21st century,
these findings will pave the way to personalized medicine.
Because Respiratory Investigation is a journal published in
Japan, studies based on the analysis of Asian genomic
information will be one of the major focuses of the journal.
We now have a tremendous opportunity to perform
therapeutic interventions for intractable diseases using novel
drugs based on recent basic research. For example, not only
targeting drugs for lung cancer but also anti-fibrotic and anti-
angiogenic drugs for lung fibrosis are currently in clinical
trials or have been recently approved. Combination trials for
lung fibrosis using new drugs will be required to obtain better
clinical evidence. Papers on such pilot-level clinical trials are
also welcome in this new journal. In addition, the JRS
Scientific Assemblies will translate the domestic Japanese
guidelines into English and publish these in this new journal.
We welcome outstanding papers from overseas to Respiratory
Investigation to promote the mutual exchange of information
and understanding of clinical problems, which are no doubt
important goals for this new English language journal. We
would be very pleased if you would consider our new journal
as one of your favorite resources of information, and we
sincerely hope for your participation to make this journal
superior and unique in the field of lung biology and
respiratory medicine.
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